237 related articles for article (PubMed ID: 17964795)
1. 2D Autocorrelation, CoMFA, and CoMSIA modeling of protein tyrosine kinases' inhibition by substituted pyrido[2,3-d]pyrimidine derivatives.
Caballero J; Fernández M; Saavedra M; González-Nilo FD
Bioorg Med Chem; 2008 Jan; 16(2):810-21. PubMed ID: 17964795
[TBL] [Abstract][Full Text] [Related]
2. Structural requirements of pyrido[2,3-d]pyrimidin-7-one as CDK4/D inhibitors: 2D autocorrelation, CoMFA and CoMSIA analyses.
Caballero J; Fernández M; González-Nilo FD
Bioorg Med Chem; 2008 Jun; 16(11):6103-15. PubMed ID: 18468903
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors.
Boschelli DH; Wu Z; Klutchko SR; Showalter HD; Hamby JM; Lu GH; Major TC; Dahring TK; Batley B; Panek RL; Keiser J; Hartl BG; Kraker AJ; Klohs WD; Roberts BJ; Patmore S; Elliott WL; Steinkampf R; Bradford LA; Hallak H; Doherty AM
J Med Chem; 1998 Oct; 41(22):4365-77. PubMed ID: 9784112
[TBL] [Abstract][Full Text] [Related]
4. 3D-QSAR studies of Checkpoint Kinase Weel inhibitors based on molecular docking, CoMFA and CoMSIA.
Yi P; Fang X; Qiu M
Eur J Med Chem; 2008 May; 43(5):925-38. PubMed ID: 17698256
[TBL] [Abstract][Full Text] [Related]
5. Structural investigation of PAP derivatives by CoMFA and CoMSIA reveals novel insight towards inhibition of Bcr-Abl oncoprotein.
San Juan AA
J Mol Graph Model; 2007 Sep; 26(2):482-93. PubMed ID: 17446106
[TBL] [Abstract][Full Text] [Related]
6. Three-dimensional quantitative structure-activity relationship studies on novel series of benzotriazine based compounds acting as Src inhibitors using CoMFA and CoMSIA.
Gueto C; Ruiz JL; Torres JE; Méndez J; Vivas-Reyes R
Bioorg Med Chem; 2008 Mar; 16(5):2439-47. PubMed ID: 18065233
[TBL] [Abstract][Full Text] [Related]
7. Insight into the structural requirements of proton pump inhibitors based on CoMFA and CoMSIA studies.
Nayana MR; Sekhar YN; Nandyala H; Muttineni R; Bairy SK; Singh K; Mahmood SK
J Mol Graph Model; 2008 Oct; 27(3):233-43. PubMed ID: 18676164
[TBL] [Abstract][Full Text] [Related]
8. A comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of anthranilamide derivatives that are multidrug resistance modulators.
Labrie P; Maddaford SP; Fortin S; Rakhit S; Kotra LP; Gaudreault RC
J Med Chem; 2006 Dec; 49(26):7646-60. PubMed ID: 17181148
[TBL] [Abstract][Full Text] [Related]
9. 3D-QSAR studies on malonyl coenzyme A decarboxylase inhibitors.
Patel MR; Talele TT
Bioorg Med Chem; 2007 Jul; 15(13):4470-81. PubMed ID: 17482825
[TBL] [Abstract][Full Text] [Related]
10. Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors.
Kamath S; Buolamwini JK
J Med Chem; 2003 Oct; 46(22):4657-68. PubMed ID: 14561085
[TBL] [Abstract][Full Text] [Related]
11. Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors.
Trumpp-Kallmeyer S; Rubin JR; Humblet C; Hamby JM; Showalter HD
J Med Chem; 1998 May; 41(11):1752-63. PubMed ID: 9599227
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor.
Rewcastle GW; Bridges AJ; Fry DW; Rubin JR; Denny WA
J Med Chem; 1997 Jun; 40(12):1820-6. PubMed ID: 9191958
[TBL] [Abstract][Full Text] [Related]
13. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking.
Du J; Lei B; Qin J; Liu H; Yao X
J Mol Graph Model; 2009 Jan; 27(5):642-54. PubMed ID: 19081278
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory mode of N-phenyl-4-pyrazolo[1,5-b] pyridazin-3-ylpyrimidin-2-amine series derivatives against GSK-3: molecular docking and 3D-QSAR analyses.
Xiao J; Guo Z; Guo Y; Chu F; Sun P
Protein Eng Des Sel; 2006 Feb; 19(2):47-54. PubMed ID: 16339768
[TBL] [Abstract][Full Text] [Related]
15. Quantitative structure-activity relationships for a series of inhibitors of cruzain from Trypanosoma cruzi: molecular modeling, CoMFA and CoMSIA studies.
Trossini GH; Guido RV; Oliva G; Ferreira EI; Andricopulo AD
J Mol Graph Model; 2009 Aug; 28(1):3-11. PubMed ID: 19376735
[TBL] [Abstract][Full Text] [Related]
16. Pharmacophore and docking-based combined in-silico study of KDR inhibitors.
Pasha FA; Muddassar M; Neaz MM; Cho SJ
J Mol Graph Model; 2009 Aug; 28(1):54-61. PubMed ID: 19447057
[TBL] [Abstract][Full Text] [Related]
17. 3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases.
Thaimattam R; Daga PR; Banerjee R; Iqbal J
Bioorg Med Chem; 2005 Aug; 13(15):4704-12. PubMed ID: 15914012
[TBL] [Abstract][Full Text] [Related]
18. QSAR studies on aminothiazole derivatives as aurora a kinase inhibitors.
Qin J; Xi L; Du J; Liu H; Yao X
Chem Biol Drug Des; 2010 Dec; 76(6):527-37. PubMed ID: 21040493
[TBL] [Abstract][Full Text] [Related]
19. 3D-QSAR studies on the inhibitors of AP-1 and NF-kappaB mediated transcriptional activation.
Qin J; Liu H; Li J; Ren Y; Yao X; Liu M
Eur J Med Chem; 2009 Jul; 44(7):2888-95. PubMed ID: 19128859
[TBL] [Abstract][Full Text] [Related]
20. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking.
Ravindra GK; Achaiah G; Sastry GN
Eur J Med Chem; 2008 Apr; 43(4):830-8. PubMed ID: 17706839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
